stockportfolio.pro
Stocks / IONS vs SNN
IONS vs SNN
Ionis Pharmaceuticals, Inc. and Smith & Nephew plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Ionis Pharmaceuticals, Inc. (IONS) | Smith & Nephew plc (SNN) | |
|---|---|---|
| Market cap | $12.2B | $12.9B |
| Revenue (latest FY) | $943.71M | $6.16B |
| Net income (latest FY) | $-381.39M | $625.00M |
| Revenue growth (5y CAGR) | 5.3% | 5.7% |
| Net margin | -40.4% | 10.1% |
| Return on equity | -78.0% | 11.8% |
| P/E ratio | — | 21.3 |
| Dividend yield | — | 2.5% |
| Profitable years (of last 10) | 3 | 4 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open IONS — free Open SNN — freeFrequently asked questions
Which is bigger, IONS or SNN?
Smith & Nephew plc is larger by market capitalization — $12.9B versus $12.2B.
Which grows faster, IONS or SNN?
Over the last five fiscal years, Smith & Nephew plc grew revenue faster — 5.7%/yr versus 5.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.